US FDA accepts for priority review Sanofi's sBLA for Sarclisa in combo with bortezomib, lenalidomide and dexamethasone ...
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for …